Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 New dopamine receptor agonists in heart failure and hypertension. Implications for future therapy.

Literature DB >> 1982088

New dopamine receptor agonists in heart failure and hypertension. Implications for future therapy.

P T Horn¹, M B Murphy.

Abstract

Entities: Disease

Mesh：

Substances：
Dopamine Agents

Year: 1990 PMID： 1982088 DOI： 10.2165/00003495-199040040-00001

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

× No keyword cloud information.

32 in total

1. Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine.

Authors: N A Lass; D Glock; L I Goldberg
Journal: Circulation Date: 1988-11 Impact factor: 29.690

2. Bromocriptine in mild to moderate hypertension.

Authors: J A Whitworth; I Macdonald; P Kincaid-Smith
Journal: Aust N Z J Med Date: 1987-08

3. Sustained hemodynamic improvement during long-term therapy with levodopa in heart failure: role of plasma catecholamines.

Authors: S I Rajfer; J D Rossen; J W Nemanich; F L Douglas; F Davis; J Osinski
Journal: J Am Coll Cardiol Date: 1987-12 Impact factor: 24.094

4. Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist.

Authors: R A Hahn; J R Wardell; H M Sarau; P T Ridley
Journal: J Pharmacol Exp Ther Date: 1982-11 Impact factor: 4.030

5. Propylbutyldopamine. Mechanism of blood pressure lowering in hypertensive patients.

Authors: A A Taylor; W H Fennell; C O Ruud; J L Pool; E B Nelson; J Z Ginos; J R Mitchell
Journal: Hypertension Date: 1984 Mar-Apr Impact factor: 10.190

6. Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels.

Authors: S I Rajfer; J D Rossen; F L Douglas; L I Goldberg; T Karrison
Journal: Circulation Date: 1986-04 Impact factor: 29.690

1. A kinetic investigation of the pulmonary metabolism of dopamine in rats shows marked differences compared with noradrenaline.

Authors: D L Scarcella; L J Bryan-Lluka
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1995-05 Impact factor: 3.000

1 in total

New dopamine receptor agonists in heart failure and hypertension. Implications for future therapy.

1. Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine.

2. Bromocriptine in mild to moderate hypertension.

3. Sustained hemodynamic improvement during long-term therapy with levodopa in heart failure: role of plasma catecholamines.

4. Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist.

5. Propylbutyldopamine. Mechanism of blood pressure lowering in hypertensive patients.

6. Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels.

7. Comparison of the cardiovascular actions of dopamine and epinine in the dog.

8. The role of alpha-adrenoceptor blockade in the antihypertensive effects of fenoldopam in humans.

9. The effects of dopexamine on the cardiovascular system of the dog.

10. Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam.

1. A kinetic investigation of the pulmonary metabolism of dopamine in rats shows marked differences compared with noradrenaline.